- Antigen dose is an important determinant of vaccines.
- A universal flu vaccine needs to induce strong and broad responses. Dose likely impacts both strength and breadth.
- For influenza, there is currently a high-dose (HD) vaccine approved for those >=65 years of age.
- HD has been shown to induce higher immunogenicity and protection against vaccine strains.
- Impact of dose on heterologous responses is uncertain.
- Long-term: Better understand and optimize dose toward inducing strong and broad immune protection. Use this knowledge as part of the COBRA vaccine development process.
- Short-term: Detailed analysis of strength and breadth of immune response following vaccination with high-dose (HD) versus standard dose (SD) influenza Fluzone vaccine.
- Open cohort of individuals who were vaccinated during the 2014/15 - 2018/19 flu seasons.
- The default vaccine was the trivalent or quadrivalent standard dose (SD, 15µg) Fluzone vaccine.
- Individuals >=65 were offered the high-dose (HD, 60µg) trivalent Fluzone vaccine.
- Analysis of immune response (HAI) for SD vs. HD individuals.
- Focus on individuals >=65 years, only look at B-strains that are in both SD and HD.